AMGEN TO WEBCAST INVESTOR CALL AT AHA 2022
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team and a clinical investigator, will discuss the Phase 2 data on olpasiran, an investigational small interfering RNA molecule designed to lower the body's production of apolipoprotein(a), a key component of Lipoprotein(a), or Lp(a), that has been associated with an increased risk of cardiovascular events and data from the Repatha FOURIER and FOURIER-open label extension studies
THOUSAND OAKS, Calif., Nov. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the American Heart Association (AHA) Scientific Sessions at 6:00 p.m. ET on Monday, Nov. 7, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team and a clinical investigator, will discuss the Phase 2 data on olpasiran, an investigational small interfering RNA molecule designed to lower the body's production of apolipoprotein(a), a key component of Lipoprotein(a), or Lp(a), that has been associated with an increased risk of cardiovascular events and data from the Repatha FOURIER and FOURIER-open label extension studies.
Additionally, although no data are being presented at AHA, the Company will provide an update on a Phase 1 study of AMG 133, a multispecific molecule being developed for obesity, during the call. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
